XML 53 R34.htm IDEA: XBRL DOCUMENT v3.8.0.1
Collaboration and Licensing Revenue (Tables)
 12 Months Ended
Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Summarized Collaboration and Licensing Revenues
The following tables summarize the amounts recorded as revenue in the consolidated statements of operations for each significant collaboration or licensing agreement for the years ended December 31, 2017, 2016 and 2015.
 
Year Ended December 31, 2017
 
Revenue Recognized From
 
Total
 
Upfront and Milestone Payments
 
Research and Development Services
 
ZIOPHARM Oncology, Inc.
$
48,313

 
$
21,499

 
$
69,812

Oragenics, Inc.
1,047

 
973

 
2,020

Fibrocell Science, Inc.
2,419

 
4,925

 
7,344

Genopaver, LLC
273

 
6,417

 
6,690

S & I Ophthalmic, LLC
—

 
755

 
755

OvaXon, LLC
—

 
1,966

 
1,966

Intrexon Energy Partners, LLC
2,500

 
8,165

 
10,665

Persea Bio, LLC
500

 
446

 
946

Ares Trading S.A.
6,389

 
4,349

 
10,738

Intrexon Energy Partners II, LLC
2,000

 
1,672

 
3,672

Intrexon T1D Partners, LLC
1,109

 
4,859

 
5,968

Harvest start-up entities (1)
2,442

 
12,790

 
15,232

Other
4,645

 
5,126

 
9,771

Total
$
71,637

 
$
73,942

 
$
145,579


(1)
For the year ended December 31, 2017, revenue recognized from collaborations with Harvest start-up entities include Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc.
 
Year Ended December 31, 2016
 
Revenue Recognized From
 
Total
 
Upfront and Milestone Payments
 
Research and Development Services
 
ZIOPHARM Oncology, Inc.
$
11,529

 
$
22,307

 
$
33,836

Oragenics, Inc.
1,047

 
1,705

 
2,752

Fibrocell Science, Inc.
2,419

 
3,523

 
5,942

Genopaver, LLC
273

 
5,844

 
6,117

S & I Ophthalmic, LLC
—

 
6,141

 
6,141

OvaXon, LLC
—

 
2,934

 
2,934

Intrexon Energy Partners, LLC
2,500

 
15,052

 
17,552

Persea Bio, LLC
500

 
778

 
1,278

Ares Trading S.A.
6,389

 
3,803

 
10,192

Intrexon Energy Partners II, LLC
2,000

 
1,169

 
3,169

Intrexon T1D Partners, LLC
821

 
1,087

 
1,908

Harvest start-up entities (1)
1,383

 
3,591

 
4,974

Other
5,572

 
7,504

 
13,076

Total
$
34,433

 
$
75,438

 
$
109,871

(1)
For the year ended December 31, 2016, revenue recognized from collaborations with Harvest start-up entities include Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc.
 
Year Ended December 31, 2015
 
Revenue Recognized From
 
Total
 
Upfront and Milestone Payments
 
Research and Development Services
 
ZIOPHARM Oncology, Inc.
$
2,855

 
$
16,451

 
$
19,306

Oragenics, Inc.
5,679

 
856

 
6,535

Fibrocell Science, Inc.
6,046

 
6,133

 
12,179

Genopaver, LLC
273

 
3,556

 
3,829

S & I Ophthalmic, LLC
—

 
4,115

 
4,115

OvaXon, LLC
—

 
2,540

 
2,540

Intrexon Energy Partners, LLC
2,500

 
10,947

 
13,447

Persea Bio, LLC
500

 
741

 
1,241

Ares Trading S.A.
3,933

 
795

 
4,728

Intrexon Energy Partners II, LLC
167

 
—

 
167

Harvest start-up entities (1)
46

 
220

 
266

Other
10,514

 
8,954

 
19,468

Total
$
32,513

 
$
55,308

 
$
87,821


(1)
For the year ended December 31, 2015, revenue recognized from collaborations with Harvest start-up entities include Thrive Agrobiotics, Inc.
Summary of Deferred Revenue
Deferred revenue consists of the following:
 
December 31,
 
2017
 
2016
Upfront and milestone payments
$
230,531

 
$
297,867

Prepaid research and development services
1,052

 
6,015

Prepaid product and service revenues
4,681

 
5,554

Other
133

 
706

Total
$
236,397

 
$
310,142

Current portion of deferred revenue
$
42,870

 
$
53,364

Long-term portion of deferred revenue
193,527

 
256,778

Total
$
236,397

 
$
310,142
Summary of Deferred Revenue by Collaborator
The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant collaboration and licensing agreement.
 
December 31,
 
2017
 
2016
ZIOPHARM Oncology, Inc.
$
90,496

 
$
138,809

Oragenics, Inc.
6,719

 
7,766

Fibrocell Science, Inc.
16,607

 
19,026

Genopaver, LLC
1,704

 
1,977

Intrexon Energy Partners, LLC
15,625

 
18,125

Persea Bio, LLC
3,500

 
4,000

Ares Trading S.A.
40,789

 
47,178

Intrexon Energy Partners II, LLC
13,833

 
15,833

Intrexon T1D Partners, LLC
8,435

 
8,653

Harvest start-up entities (1)
18,400

 
20,208

Other
14,423

 
16,292

Total
$
230,531

 
$
297,867


(1)
As of December 31, 2017 and December 31, 2016, the balance of deferred revenue for collaborations with Harvest start-up entities includes Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc.